Clene: CNM-Au8 shows 60% reduced death risk (HR 0.431, p=0.0002) and 28% NfL reduction in ALS trial OLE

Clene Inc.

Survival analysis of CNM-Au8 30 mg vs matched PRO-ACT controls up to 3.5 years: HR 0.431 (95% CI 0.276-0.672, p=0.0002).
NfL responder subset (n=55) showed average 28% NfL reduction at Week 76 (GMR 0.72, p<0.0001), indicating decreased axonal loss.
More than 650 patient-years of CNM-Au8 treatment exposure with no identified safety signals.
Data presented at 2024 ENCALS meeting; includes up to 42 months survival follow-up and 76 weeks biomarker results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.